ABX-CRO

Executive Summary

ABX-CRO is a German-based full-service contract research organization (CRO) specializing in neuroscience, oncology, and molecular imaging. Founded in 1998 and headquartered in Dresden, the company offers a unique translational medicine approach that bridges preclinical and clinical research, aiming to accelerate drug development from bench to bedside. With a focus on cutting-edge biomarkers and imaging techniques, ABX-CRO supports pharmaceutical and biotech clients in designing and executing studies across therapeutic areas. As a private, pre-clinical-stage company, it has established a reputation for expertise in complex disease models and innovative endpoints, positioning itself as a key partner for early-stage drug developers seeking to de-risk their assets.

Upcoming Catalysts (preview)

• Q2 2026Announcement of new strategic partnership or major contract win60% success
• Q4 2026Launch of novel imaging biomarker service for oncology40% success
• Q3 2026Publication of positive results from a collaborative preclinical study in neuroscience50% success